An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing research now caught up in Trump administration funding delays.
The early results — a scientific first — were published Wednesday even as study participants worried that politics could cut their access to a possible lifeline.
